ASCO 2022 on EFS by Residual Cancer Burden After Neoadjuvant Pembro + Chemo vs. Placebo + Chemo for eTNBC: Exploratory Analysis From the KEYNOTE-522
By
ASCO 2022 Conference Coverage
FEATURING
Lajos Pusztai
June 14, 2022
Login to view comments.
Click here to Login